Efﬁcacy and Safety of Exenatide Once WeeklyVersusMetformin,Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2Diabetes (DURATION-4) A 26-week double-blind study DAVIDRUSSELL -JONES,MD1 ROBERT M. C UDDIHY ,MD2 MARKOLF HANEFELD ,MD3 AJAYKUMAR,MD4 JOSEG. G ONZÁLEZ ,MD5MELANIE CHAN,PHD6 ANNEM. W OLKA,PHD6 MARILYN K. B OARDMAN ,PHARMD6 ON BEHALF OF THE DURATION-4 S TUDY GROUP* OBJECTIVE dTo test the safety and ef ﬁcacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimallytreated (diet and exercise) drug-naive patients with type 2 diabetes. RESEARCH DESIGN AND METHODS dPatients were randomized to subcutaneous (SC) EQW 2.0 mg + oral placebo ( n= 248), MET 2,000 mg/day + SC placebo ( n=2 4 6 ) ,P I O4 5 mg/day + SC placebo ( n=1 6 3 ) ,o rS I T A1 0 0m g / d a y+S Cp l a c e b o( n=1 6 3 )f o r2 6w e e k s .